LEXX (lexariabioscience.com) Net Profit

Corporate emblem and logo of Lexaria Bioscience (LEXX)

Lexaria Bioscience's ambition to occupy a narrow patent licensing niche may seem risky, yet the company's net profit figures demonstrate a different trend. The -0.01 mark indicates a level where calculated revenues confirm the model's sustainability. This is based on long-term R&D contracts that are independent of GDP and the recruitment of top chemists through profit-sharing prospects.

LEXX (lexariabioscience.com) Company Net Income history from 07/04/2022 to 10/29/2026

Financial and market metric breakdowns for lexariabioscience.com (LEXX)

- price and consensus price forecast:
Stock Quotes Lexaria Bioscience Corp.|LEXX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Lexaria Bioscience Corp.|LEXX - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Lexaria Bioscience|LEXX - Company Book Value|Market-to-Book Ratio lexariabioscience.com|LEXX - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Lexaria Bioscience|LEXX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Lexaria Bioscience Corp.|LEXX - Company Aggregate Debts|Debts to Book Value Lexaria Bioscience Corp.|LEXX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Lexaria Bioscience|Quick Liquidity lexariabioscience.com
- net income and valuation multiples indicators:
LEXX - Net Profit
Fundamental valuation:LEXX Lexaria
Flagship merchandise of Lexaria Bioscience Corp

The licensing of DehydraTECH technology across various therapeutic areas directly impacts the operational efficiency of Lexaria Bioscience (LEXX), determining the volume of incoming cash flows. By analyzing the company's net income, an investor assesses the final financial result after deducting all operating expenses and taxes, which allows for the differentiation of real business growth from temporary stagnation and an evaluation of capital stability.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Company Net Income Theravance Biopharma, Inc. TBPH|Aquestive Therapeutics Inc - Company Net Income|scPharma - Net Profit|Company Net Income Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals) - Net Income|Company Profit SXTC|EPRX (Eupraxia Pharmaceuticals, Inc.) - Net Profit|Net Profit BioHarvest Sciences, Inc.|Company Net Income Invizyne Technologies, Inc. (EXOZ)|ORMP (oramed.com) - Final Profit|Net Profit ENTX (Entera Bio)|Net Financial Result ipatherapeutics.com (HYFT)|ABVC BioPharma, Inc. - Net Profit|CPIX - Net Profit|QNTM (Quantum BioPharma Limited) - Net Income|FibroGen Corporation - Final Profit|TELO (Telomir Pharmaceuticals) - Net Profit|Company Net Income RANI|Net Profit SNYR|Net Financial Result rallybio.com|Company Net Income Pulmatrix Corp PULM|Pheton Holdings Limited (PTHL) - Company Net Income|APM - Company Net Income|Net Financial Result lyratherapeutics.com LYRA|IBO: Net Profit|Net Income TNF Pharmaceuticals, Inc.|YCBD (cbdMD Inc.) - Net Profit|PainReform Corp (PRFX) - Net Financial Result|Net Profit CYTO|LIPO - Company Net Income|Company Net Income OptiNose OPTN|PIRS: Company Profit|Procaps Group SA - Net Profit|Petros Pharma (PTPI) - Net Income|QLI: Net Profit|Company Net Income acelyrin.com (SLRN)|Company Net Income TFF Pharmaceuticals, Inc.